Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Average Target Price from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at about $60,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares in the last quarter. Ballentine Partners LLC bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at about $104,000. Hsbc Holdings PLC bought a new position in shares of Theravance Biopharma during the 2nd quarter valued at about $108,000. Finally, XTX Topco Ltd bought a new position in shares of Theravance Biopharma during the 2nd quarter valued at about $129,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $9.88 on Monday. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $11.71. The firm has a market cap of $485.80 million, a PE ratio of -9.78 and a beta of 0.23. The business has a fifty day moving average of $9.05 and a 200-day moving average of $8.77.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the previous year, the business earned ($0.17) earnings per share. On average, analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.